Cargando…
Angiogenesis inhibitors in the treatment of prostate cancer
Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of castrate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets the reliance of tumor growth on the formation of new blood vesse...
Autores principales: | Hwang, Clara, Heath, Elisabeth I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922886/ https://www.ncbi.nlm.nih.gov/pubmed/20678204 http://dx.doi.org/10.1186/1756-8722-3-26 |
Ejemplares similares
-
Targeting Angiogenesis in Prostate Cancer
por: Melegh, Zsombor, et al.
Publicado: (2019) -
Angiogenesis Inhibition in Prostate Cancer: An Update
por: Sarkar, Chandrani, et al.
Publicado: (2020) -
Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
por: Ioannidou, Evangelia, et al.
Publicado: (2021) -
Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017) -
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
por: Wang, Ying-Qing, et al.
Publicado: (2013)